Clinical Trials Logo
  1. Home
  2. Recurrent Cancer
  3. NCT05855811

PREventing Second Cancers With DOSTARlimab — PREDOSTAR  

Recurrent Cancer Clinical Trial

Official title:
A Multicenter, Open-label, Randomized Phase II Study Aiming to Assess the Clinical Impact of Dostarlimab on Occurrence of Second Primary Cancer in Patients With Cured Primary Cancer

Clinical Trial Summary

PredoSTAR is a multicenter, randomized, open-label phase II study proposed to patients at high risk of SPC and in whom the treatment of the FPC does not include immunotherapy. Dostarlimab treatment will be started within 6 months after the completion of treatment for localized FPC (i.e. after the end of last CT, RT cure or surgery with a wash-out period of 4 weeks before to start Dostarlimab). Eligible patients will be randomized (1:1) to receive: - Arm Dostarlimab : 4 intravenous (IV) injections of dostarlimab, Q3W or - Arm No treatment

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05855811
Study type Interventional
Source Centre Leon Berard
Contact Jean-Yves BLAY, MD, PhD
Phone 4 78 78 51 26
Email jean-yves.blay@lyon.unicancer.fr
Status Recruiting
Phase Phase 2
Start date July 26, 2023
Completion date March 26, 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Recruiting NCT05415475 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT04596865 - Recurrence After Whipple's (RAW) Study
Recruiting NCT06103617 - Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Phase 2
Completed NCT05364905 - Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
Recruiting NCT05396300 - A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT05359445 - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Phase 1
Not yet recruiting NCT04889742 - Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Phase 2
Recruiting NCT05189054 - Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Completed NCT03132038 - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Not yet recruiting NCT02410187 - SBRT for Extra-cranial Oligorecurrent Tumor Phase 2
Not yet recruiting NCT04784221 - Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse Phase 2
Recruiting NCT05626829 - Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma Phase 2
Completed NCT03941262 - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Phase 1
Not yet recruiting NCT06372574 - A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors Phase 1
Completed NCT05200195 - Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Completed NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling